Athena Gold Corp

Alzheon is set to present Phase 3 trial data for ALZ-801 in April 2025, a drug designed to prevent the formation of toxic beta-amyloid plaques in early Alzheimer's patients with the ApoE4 gene.

• Athira Pharma presented Phase 2/3 LIFT-AD trial results of fosgonimeton for Alzheimer's at CTAD, Madrid, from October 29 to November 1, 2024. • The LIFT-AD trial did not meet statistical significance for its primary endpoint, the Global Statistical Test, at 26 weeks compared to placebo. • Subgroup analysis showed cognitive and functional improvements in patients with moderate Alzheimer's and APOE4 carriers treated with fosgonimeton. • ATH-1105, a next-generation small molecule HGF modulator, is being advanced for ALS and Alzheimer's, with Phase 1 trial data expected by year-end 2024.

• The Alzheimer's disease therapeutic pipeline is expanding beyond amyloid and tau targets, with 32 therapeutics in 48 Phase III trials exploring neuroprotection, neurotransmitters, and inflammation. • Recent approvals of anti-amyloid antibodies like Leqembi and Kisunla have shown modest clinical benefits but also carry risks, prompting the development of alternative approaches. • Several Phase III candidates, such as Athira's fosgonimeton, Anavex's ANAVEX 2-73, and Novo Nordisk's semaglutide, target different mechanisms like neurotrophic factors, neuronal homeostasis, and neuroinflammation. • Experts suggest that combination therapies and brain-healthy lifestyles may be essential for effectively managing the heterogeneous nature of Alzheimer's disease.

• Athira Pharma's fosgonimeton did not meet the primary endpoint in the Phase II/III LIFT-AD trial for mild-to-moderate Alzheimer's disease. • The trial failed to show statistically significant improvement in cognition and function compared to placebo after 26 weeks of treatment. • Subgroup analyses showed some improvements in cognition and function in patients with moderate Alzheimer's and APOE4 carriers. • Despite the setback, Athira Pharma believes the data suggest potential benefits of HGF pathway modulation on neuronal health.